# Teleflex share price today (Teleflex Incorporated, TFX)

> Teleflex Incorporated's share price has risen faster than its earnings: +12.4% in a year, against −1,472.7% for earnings per share. TFX · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/tfx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $139.95 (+12.4% in a year)
- P/E: 81.9× (higher than 83% of the last 3.3 years)
- Revenue (Jun 2026): $570 M
- Profit (Jun 2026): $99.7 M
- Operating margin: 10.1%
- ROE: −29%, FY25
- ROIC: 3.6%, against a 6.9% cost of capital: −3.3 points
- Profit that came in as cash: 189%, last 3 years

The main question: the share price moved +12.4% in a year while yearly earnings per share moved −1,472.7%. The difference came from the market paying a higher multiple. ## What is the Teleflex share price today? Teleflex Incorporated's share price was $139.95 at the close on 3 November 2026. It has been rising for 6 weeks. That is 11.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $103 and $140, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 10 years the share price moved −23% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Teleflex pay? Teleflex Incorporated paid $1.36 per share over the last four reported quarters. The most recent declaration was $0.34 for Jun 2026. At today's price of $139.95 that is a yield of 0.97%, based on dividends already paid, not a forecast. ## Which stock lists is Teleflex on? Teleflex is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Teleflex profitable? Teleflex Incorporated earned $99.7 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $906 M. That is 17.5% of the quarter's revenue. The same quarter a year earlier earned $80.0 M. 2 of the last 8 reported quarters were loss-making. For the full year, FY25 profit was −$906 M (−1,399.8% on the year before). ## How much revenue does Teleflex make, and is it growing? Teleflex Incorporated reported $570 M of revenue in the Jun 2026 quarter. Over 4 years it has grown −8.2% a year on average. The last full year, FY25, came in at $2.0 B. The quarterly figures for FY25 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $2.0 B, +17.2% on the year before. ## How much of every $100 of sales does Teleflex keep? Teleflex Incorporated's operating margin was 10.1% in the Jun 2026 quarter. Across 5 years it has been between 7.7% and 20.2%. The latest quarter is within that range. Why the margin moved: operating margin changed −6.5 percentage points on the year while gross margin changed +2.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Teleflex's profit turning into cash? Over the last 3 years, 189% of Teleflex Incorporated's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $341 M of operating cash against −$906 M of profit. After $95.2 M of spending on assets, $245 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Teleflex's cash go? Teleflex Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $232 M on assets over the last 3 years. Averaged over those years that is 3.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $232 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Teleflex's P/E ratio, and how does it compare with its own history? Teleflex Incorporated's P/E is 81.9×, near the high end of its own history: higher than 83% of past readings. Its usual P/E (the middle reading) is 32.6×, over 3.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −1,472.7% while the price moved +12.4%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −12.8% a year; about −49.1% a year came from earnings growth and about +36.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Teleflex business getting better or worse? Teleflex Incorporated's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Teleflex earn on its capital? Teleflex Incorporated earned a ROE of −29% in FY25. Its return on capital used (ROIC) is 3.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −45.4% net margin and 0.29× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −45.4% net margin × 0.29× asset turnover × 2.22× leverage (assets divided by equity) ≈ −29.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.6% − 6.9% = −3.3 percentage points. The 6.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 3.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 5.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Teleflex have too much debt? Teleflex Incorporated has total debt of $2.9 B against shareholder equity of $2.9 B as of Jun 2026, so its debt is 1.01× its equity. Year by year, that ratio went from 0.53 in FY21 to 0.90 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Teleflex shareholding pattern? 10.0% of Teleflex Incorporated's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Teleflex from balance-sheet trouble? For Teleflex Incorporated, the Z-score is 2.12. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 2.12 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Teleflex rank in its industry? 42.0 out of 100, rank 22 of 30 in Medical Instruments & Supplies, with 71% of the evidence available. Teleflex Incorporated scores 42.0 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 22. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 10.9 + 8.3 + 11 + 11.8 = 42. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Teleflex compared with? Teleflex ranks 22 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 42.0 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. Teleflex Incorporated this page TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.9/35 · Revenue 52.4% · Profit -637% · Operating margin change -12.9 points · 83% evidence Capital efficiency 8.3/25 · ROCE 0.9% · Operating margin 10.1% · 76% evidence Valuation 11.0/20 · P/E -5.4× · PEG n/a · 15% evidence Relative strength 11.8/20 · Lead over its industry -2.5% · Lead over S&P 500 7.5% · 1 year 27.9% · 100% evidence · 2 of 12 weeks ahead Exact sum: 10.9 + 8.3 + 11 + 11.8 = 42 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Teleflex in size? Teleflex is the 15th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Avantor, Inc., AptarGroup, Inc. and Bausch + Lomb Corporation. Just below it: MiniMed Group, Inc., Merit Medical Systems, Inc. and ICU Medical, Inc. ### Medical Instruments & Supplies companies close in size

1. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) $10.6 billion
2. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) $9 billion
3. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) $7.2 billion
4. Teleflex Incorporated $5.9 billion
5. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) $5.3 billion
6. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) $5 billion
7. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) $4 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [GXO Logistics, Inc.](https://www.sectoralpha.in/us/stocks/gxo) $6 billion · Integrated Freight & Logistics
2. [GRAIL, Inc.](https://www.sectoralpha.in/us/stocks/gral) $6 billion · Diagnostics & Research
3. Teleflex Incorporated $6 billion
4. [Triple Flag Precious Metals Corp.](https://www.sectoralpha.in/us/stocks/tfpm) $6 billion · Other Precious Metals & Mining
5. [AutoNation, Inc.](https://www.sectoralpha.in/us/stocks/an) $5.9 billion · Auto & Truck Dealerships

## What else do people ask about Teleflex? ### What were Teleflex's latest quarterly results? Teleflex Incorporated reported revenue of $570 M and net profit of $99.7 M for the Jun 2026 quarter. Earnings per share were $2.29. The operating margin was 10.1% (as of 3 November 2026). ### What is Teleflex's market cap? Teleflex Incorporated's market capitalisation is $5.9 B at a stock price of $139.95. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Teleflex performing? Teleflex Incorporated's share price has been rising for 6 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Teleflex's stock price go up? This page does not forecast Teleflex Incorporated's stock price. What it shows instead: the stock price is $139.95, and it has been rising for 6 weeks. Its P/E of 81.9× is higher than 83% of its own last 3 years (as of 3 November 2026). ### Is Teleflex's profit real cash? Yes, over the last 3 years, 189% of Teleflex Incorporated's reported profit came in as cash from operations. The latest year was lower at -38%, so the trend is worth watching. In FY25, operating cash was $341 M against reported profit of −$906 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Teleflex in its business cycle? Teleflex Incorporated's FY25 operating margin was 14.6%, against a 5-year range of 7.7% to 20.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 10.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Teleflex story? The main question: the share price moved +12.4% in a year while yearly earnings per share moved −1,472.7%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Teleflex a stock worth studying right now? What the numbers show: Teleflex Incorporated's share price has risen faster than its earnings: +12.4% in a year, against −1,472.7% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.